Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2018-10-23
Target enrollment:
Participant gender:
Summary
This is a Phase II therapeutic trial combining Decitabine days 1-5 with oral Vorinostat twice
daily days 6-15 followed by a single infusion of CD3-/CD19- enriched donor natural killer
(NK) cells on day 17 and a short course of Interleukin-2 (IL-2) to facilitate NK cell
survival and expansion. Two courses of treatment will be given separated by 6-8 weeks. The
intent is to administer all treatment in the outpatient setting.